Immunome Inc. reporting persons Sirenia Capital Management and Alex Silverstein reported beneficial ownership of 6,895,000 shares of common stock, representing 6.1% of the class based on 113,133,199 shares outstanding as of February 27, 2026. The holdings are shown as shared voting and dispositive power. The filing is a Schedule 13G joint statement filed under Rule 13d-1(k).
Positive
None.
Negative
None.
Insights
Sirenia reports a 6.1% shared stake in Immunome, disclosed via a joint Schedule 13G.
The filing lists 6,895,000 shares held by a fund and managed account with shared voting and dispositive power. The percentage is calculated from 113,133,199 shares outstanding as of February 27, 2026.
Cash‑flow treatment and any planned transactions are not specified in the excerpt; subsequent filings would show changes to this passive ownership picture.
Disclosure frames ownership and filing mechanics, not activist intent.
The statement was filed jointly by Sirenia and Alex Silverstein and includes a Joint Filing Agreement (Exhibit 99.1). It uses Rule 13d-1(k) treatment, which typically indicates passive reporting rather than an active solicitation.
Investors should note the filing reports shared voting and dispositive power rather than sole control.
Key Figures
Shares beneficially owned:6,895,000 sharesPercent of class:6.1%Shares outstanding:113,133,199 shares+2 more
5 metrics
Shares beneficially owned6,895,000 sharesReported by Sirenia and Alex Silverstein
Percent of class6.1%Calculated using shares outstanding as of February 27, 2026
Shares outstanding113,133,199 sharesAs of February 27, 2026 per issuer Form 10-K
CUSIP45257U108Immunome common stock CUSIP
Filing date (signature)05/15/2026Signatures on Schedule 13G
"The information required by Item 4(a) is set forth in Row 9 of the cover page"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
shared dispositive powerregulatory
"Shared Dispositive Power 6,895,000.00"
Rule 13d-1(k)regulatory
"jointly in accordance with the provisions of Rule 13d-1(k)"
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Immunome Inc.
(Name of Issuer)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
45257U108
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
45257U108
1
Names of Reporting Persons
Sirenia Capital Management LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
6,895,000.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
6,895,000.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
6,895,000.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.1 %
12
Type of Reporting Person (See Instructions)
IA, PN
SCHEDULE 13G
CUSIP Number(s):
45257U108
1
Names of Reporting Persons
Alex Silverstein
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
6,895,000.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
6,895,000.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
6,895,000.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.1 %
12
Type of Reporting Person (See Instructions)
HC, IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Immunome Inc.
(b)
Address of issuer's principal executive offices:
18702 N. Creek Parkway, Suite 100, Bothell, WA 98011
Item 2.
(a)
Name of person filing:
This statement is filed by:
(i) Sirenia Capital Management LP ("Sirenia") with respect to the common stock, par value $0.0001 per share ("Common Stock"), of Immunome, Inc. (the "Issuer") held by an investment fund (the "Sirenia Fund") and managed account (the "Sirenia Account") it manages; and
(ii) Alex Silverstein ("Mr. Silverstein"), the managing member of Sirenia Capital Management GP LLC, the general partner of Sirenia, with respect to the Common Stock held by the Sirenia Fund and Sirenia Account.
The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."
The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the securities reported herein.
Sirenia and Mr. Silverstein have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 99.1, pursuant to which they have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Securities Exchange Act of 1934 (the "Act").
(b)
Address or principal business office or, if none, residence:
The address of the principal business office of Sirenia and Mr. Silverstein is 1674 Meridian Avenue, Suite 320, Miami Beach, FL 33139.
(c)
Citizenship:
Sirenia is a Delaware limited partnership. Mr. Silverstein is a United States citizen.
(d)
Title of class of securities:
Common Stock, par value $0.0001 per share
(e)
CUSIP Number(s):
45257U108
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 113,133,199 shares of Common Stock outstanding as of February 27, 2026, as reported in the Issuer's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission on March 3, 2026.
(b)
Percent of class:
6.1%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
(ii) Shared power to vote or to direct the vote:
The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
(iii) Sole power to dispose or to direct the disposition of:
The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
(iv) Shared power to dispose or to direct the disposition of:
The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
See Item 2(a).
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Sirenia Capital Management LP
Signature:
/s/ Kolby Loft
Name/Title:
Kolby Loft, General Counsel & Chief Compliance Officer
What stake does Sirenia Capital report in Immunome (IMNM)?
Sirenia reports beneficial ownership of 6,895,000 shares, equal to 6.1% of common stock. This percentage uses a base of 113,133,199 shares outstanding as of February 27, 2026 from the issuer's Form 10-K.
Who filed the Schedule 13G for IMNM and why is it joint?
The Schedule 13G was filed jointly by Sirenia Capital Management and Alex Silverstein. They executed a Joint Filing Agreement (Exhibit 99.1) to report ownership under Rule 13d-1(k) as required by the Exchange Act.
Does the filing show whether Sirenia has sole voting power over IMNM shares?
The filing shows 0 sole voting power and 6,895,000 shared voting power. It records shared dispositive power for the same number of shares rather than sole control of voting or disposition.
What outstanding share count did the filing use to calculate the 6.1%?
The 6.1% percent is calculated using 113,133,199 shares outstanding as of February 27, 2026, as reported in Immunome's Annual Report on Form 10-K for the fiscal year ended December 31, 2025.
Does this Schedule 13G indicate Sirenia plans to acquire more IMNM shares?
The statement reports current beneficial ownership and uses Rule 13d-1(k); it does not state any plans to acquire additional shares. The filing does not disclose any planned purchases or sales.
